Metabolism of lysergic acid diethylamide (LSD): an update

References

• Abraham HD, Aldridge AM, Gogia P. 1996. The psychopharmacology of hallucinogens. Neuropsychopharmacology. 14:285–298.
   PubMed Web of Science ®Google Scholar
• Aghajanian GK, Bing OH. 1964. Persistence of lysergic acid diethylamide in the plasma of human subjects. Clin Pharmacol Ther. 5:611–614.
   PubMed Web of Science ®Google Scholar
• Araújo AM, Carvalho F, Bastos ML, Pinho PG, Carvalho M. 2015. The hallucinogenic world of tryptamines: an updated review. Arch Toxicol. 89:1151–1173.
   PubMed Web of Science ®Google Scholar
• Axelrod J, Brady RO, Witkop B, Evarts EV. 1957. The distribution and metabolism of lysergic acid diethylamide. Ann N Y Acad Sci. 66:435–444.
   PubMed Web of Science ®Google Scholar
• Back DJ, Singh JK. 1976. The biliary excretion of [3H] lysergic acid diethylamide in Wistar and Gunn rats. Experientia. 32:616–617.
   PubMedGoogle Scholar
• Bogenschutz MP. 2013. Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin. Curr Drug Abuse Rev. 6:17–29.
   PubMedGoogle Scholar
• Bogenschutz MP, Johnson MW. 2016. Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry. 64:250–258.
   PubMed Web of Science ®Google Scholar
• Boyd E. 1959. The metabolism of lysergic acid diethylamide. Arch Int Pharmacodyn Ther. 120:292.
   PubMedGoogle Scholar
• Boyd E, Rothlin E, Bonner J, Slater I, Hodge H. 1955. Preliminary studies of the metabolism of lysergic acid diethylamide using radioactive carbon-marked molecules. J Nerv Ment Dis. 122:470–471.
   PubMedGoogle Scholar
• Cai J, Henion J. 1996. Elucidation of LSD in vitro metabolism by liquid chromatography and capillary electrophoresis coupled with tandem mass spectrometry. J Anal Toxicol. 20:27–37.
   PubMed Web of Science ®Google Scholar
• Canezin J, Cailleux A, Turcant A, Le Bouil A, Harry P, Allain P. 2001. Determination of LSD and its metabolites in human biological fluids by high-performance liquid chromatography with electrospray tandem mass spectrometry. J Chromatogr B Biomed Sci Appl. 765:15–27.
   PubMed Web of Science ®Google Scholar
• Chung A, Hudson J, McKay G. 2009. Validated ultra-performance liquid chromatography-tandem mass spectrometry method for analyzing LSD, iso-LSD, nor-LSD, and OH-LSD in blood and urine. J Anal Toxicol. 33:253–259.
   PubMed Web of Science ®Google Scholar
• Clarkson ED, Lesser D, Paul BD. 1998. Effective GC-MS procedure for detecting iso-LSD in urine after base-catalyzed conversion to LSD. Clin Chem. 44:287–292.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. 2017. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev. 49:84–91.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ, Pereira CL, Silva DD. 2018. Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions. Curr Mol Pharmacol. 12:1–11.
   Web of Science ®Google Scholar
• Dolder PC, Liechti ME, Rentsch KM. 2015. Development and validation of a rapid turboflow LC-MS/MS method for the quantification of LSD and 2-oxo-3-hydroxy LSD in serum and urine samples of emergency toxicological cases. Anal Bioanal Chem. 407:1577–1584.
   PubMed Web of Science ®Google Scholar
• Dolder PC, Liechti ME, Rentsch KM. 2018. Development and validation of an LC-MS/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial. J Clin Lab Anal. 32:e22265–1584.
   PubMed Web of Science ®Google Scholar
• Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME. 2015. Pharmacokinetics and concentration-effect relationship of oral LSD in humans. Int J Neuropsychopharmacol. 19:pyv072.
   PubMed Web of Science ®Google Scholar
• Dolder PC, Schmid Y, Muller F, Borgwardt S, Liechti ME. 2016. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacol. 41:2638–2646.
   PubMed Web of Science ®Google Scholar
• Dolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, Liechti ME. 2017. Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clin Pharmacokinet. 56:1219–1230.
   PubMed Web of Science ®Google Scholar
• Faed E, McLeod W. 1973. A urine screening test for lysergide (LSD-25). J Chromatogr Sci. 11:4–6.
   Web of Science ®Google Scholar
• Fantegrossi WE, Murnane KS, Reissig CJ. 2008. The behavioral pharmacology of hallucinogens. Biochem Pharmacol. 75:17–33.
   PubMed Web of Science ®Google Scholar
• Favretto D, Frison G, Maietti S, Ferrara SD. 2007. LC-ESI-MS/MS on an ion trap for the determination of LSD, iso-LSD, nor-LSD and 2-oxo-3-hydroxy-LSD in blood, urine and vitreous humor. Int J Legal Med. 121:259–265.
   PubMed Web of Science ®Google Scholar
• Foltz R. 1995. LSD: pharmacokinetics and newly identified metabolites. Proceedings of the California Association of Toxicologists; Feb 1995; San Jose (CA): p. 20–29.
   Google Scholar
• Foltz R, Reuschel S. 1998. Investigation of the metabolism of LSD and the development of methods for detecting LSD use. NWBR. 98:1–29.
   Google Scholar
• Francom P, Andrenyak D, Lim HK, Bridges RR, Foltz RL, Jones RT. 1988. Determination of LSD in urine by capillary column gas chromatography and electron impact mass spectrometry. J Anal Toxicol. 12:1–8.
   PubMed Web of Science ®Google Scholar
• Freedman D, Coquet C. 1965. Regional and subcellular distribution of LSD and effects on 5-HT levels. Pharmacologist. 7:183.
   Google Scholar
• Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R. 2014. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 202:513–520.
   PubMed Web of Science ®Google Scholar
• Gomes MM, Dörr FA, Catalani LH, Campa A. 2012. Oxidation of lysergic acid diethylamide (LSD) by peroxidases: a new metabolic pathway. Forensic Toxicol. 30:87–97.
   Web of Science ®Google Scholar
• Halberstadt AL. 2015. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res. 277:99–120.
   PubMed Web of Science ®Google Scholar
• Haley T, Rutschmann J. 1957. Brain concentrations of LSD-25 (delysid) after intracerebral or intravenous administration in conscious animals. Experientia. 13:199–200.
   PubMedGoogle Scholar
• Halpern JH, Pope HG. Jr. 2003. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend. 69:109–119.
   PubMed Web of Science ®Google Scholar
• Hoch P. 1956. Studies in routes of administration and counteracting drugs. In: Cholden L, editor. Lysergic acid diethyla-mide and mescaline in experimental psychiatry. New York (NY): Grune and Stratton, Inc.; p. 8–12.
   Google Scholar
• Hoffer A. 1967. A program for the treatment of alcoholism: LSD, malvaria and nicotinic acid. In: Abramson HA, editor. The use of LSD in psychotherapy and alcoholism. Indianapolis (IN): BobbsMerrill; p. 343–406.
   Google Scholar
• Hofmann A. 1979. How LSD originated. J Psychedelic Drugs. 11:53–60.
   PubMed Web of Science ®Google Scholar
• Hoja H, Marquet P, Verneuil B, Lotfi H, Dupuy JL, Lachatre G. 1997. Determination of LSD and N-demethyl-LSD in urine by liquid chromatography coupled to electrospray ionization mass spectrometry. J Chromatogr B Biomed Sci Appl. 692:329–335.
   PubMed Web of Science ®Google Scholar
• Hollister LE. 1984. Effects of hallucinogens in humans. In: Jacobs BL, editor. Hallucinogens: neurochemical, behavioral, and clinical perspectives. New York (NY): Raven Press; p. 19–33.
   Google Scholar
• Holze F, Duthaler U, Vizeli P, Müller F, Borgwardt S, Liechti ME. 2019. Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects. Br J Clin Pharmacol. 85:1474–1483.
   PubMed Web of Science ®Google Scholar
• Hovda LR, Brutlag AG, Poppenga RH, Peterson KL. 2016. Chapter 33, LSD (lysergic acid diethylamide). In: Blackwell W, editor. Blackwell’s five-minute veterinary consult clinical companion: small animal toxicology. Hoboken (NJ): John Wiley & Sons; p. 259.
   Google Scholar
• Idanpaan-Heikkila JE, Schoolar JC. 1969. LSD: autoradiographic study on the placental transfer and tissue distribution in mice. Science. 164:1295–1297.
   PubMed Web of Science ®Google Scholar
• Inoue T, Niwaguchi T, Murata T. 1980a. Effects of inducers and/or inhibitors on metabolism of lysergic acid diethylamide in rat liver microsomes. Xenobiotica. 10:913–920.
   PubMed Web of Science ®Google Scholar
• Inoue T, Niwaguchi T, Murata T. 1980b. Enzymic formation of dehydrogenated and hydroxylated metabolites from lysergic acid diethylamide by rat liver microsomes. Xenobiotica. 10:343–348.
   PubMed Web of Science ®Google Scholar
• Jang M, Kim J, Han I, Yang W. 2015. Simultaneous determination of LSD and 2-oxo-3-hydroxy LSD in hair and urine by LC-MS/MS and its application to forensic cases. J Pharm Biomed Anal. 115:138–143.
   PubMed Web of Science ®Google Scholar
• Johansen SS, Jensen JL. 2005. Liquid chromatography-tandem mass spectrometry determination of LSD, ISO-LSD, and the main metabolite 2-oxo-3-hydroxy-LSD in forensic samples and application in a forensic case. J Chromatogr B Analyt Technol Biomed Life Sci. 825:21–28.
   PubMed Web of Science ®Google Scholar
• Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. 2018. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 142:143–166.
   PubMed Web of Science ®Google Scholar
• Karch SB. 2006. Drug abuse handbook. New York (NY): CRC Press. Chapter 1, Criminalistics – introduction to controlled substances.
   Google Scholar
• Klette KL, Anderson CJ, Poch GK, Nimrod AC, ElSohly MA. 2000. Metabolism of lysergic acid diethylamide (LSD) to 2-oxo-3-hydroxy LSD (OH-LSD) in human liver microsomes and cryopreserved human hepatocytes. J Anal Toxicol. 24:550–556.
   PubMed Web of Science ®Google Scholar
• Klette KL, Horn CK, Stout PR, Anderson CJ. 2002. LC-mS analysis of human urine specimens for 2-oxo-3-hydroxy LSD: method validation for potential interferants and stability study of 2-oxo-3-hydroxy LSD under various storage conditions. J Anal Toxicol. 26:193–200.
   PubMed Web of Science ®Google Scholar
• Lanz U, Cerletti A, Rothlin E. 1955. Distribution of lysergic acid diethylamide in the organism. Helv Physiol Pharmacol Acta. 13:207.
   PubMedGoogle Scholar
• Levine B, Jenkins AJ. 2003. Hallucinogens. Principles of forensic toxicology. 2nd ed. Washington (DC): AACC Press; p. 265–284.
   Google Scholar
• Levy G. 1969. Pharmacokinetics of LSD effect. Clin Pharmacol Ther. 10:134.
   PubMed Web of Science ®Google Scholar
• Li Z, McNally AJ, Wang H, Salamone S. 1998. Stability study of LSD under various storage conditions. J Anal Toxicol. 22:520–525.
   PubMed Web of Science ®Google Scholar
• Liechti ME. 2017. Modern clinical research on LSD. Neuropsychopharmacol. 42:2114.
   PubMed Web of Science ®Google Scholar
• Lim HK, Andrenyak D, Francom P, Foltz RL, Jones RT. 1988. Quantification of LSD and N-demethyl-LSD in urine by gas chromatography/resonance electron capture ionization mass spectrometry. Anal Chem. 60:1420–1425.
   PubMed Web of Science ®Google Scholar
• Luethi D, Hoener MC, Krahenbuhl S, Liechti ME, Duthaler U. 2019. Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: implications for clinical LSD use. Biochem Pharmacol. 164:129–138.
   PubMed Web of Science ®Google Scholar
• Malle E, Furtmuller PG, Sattler W, Obinger C. 2007. Myeloperoxidase: a target for new drug development? Br J Pharmacol. 152:838–854.
   PubMed Web of Science ®Google Scholar
• Mardal M, Johansen SS, Thomsen R, Linnet K. 2017. Advantages of analyzing postmortem brain samples in routine forensic drug screening-case series of three non-natural deaths tested positive for lysergic acid diethylamide (LSD). Forensic Sci Int. 278:14–18.
   PubMed Web of Science ®Google Scholar
• Martin R, Schurenkamp J, Gasse A, Pfeiffer H, Kohler H. 2013. Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS/MS. Int J Legal Med. 127:593–601.
   PubMed Web of Science ®Google Scholar
• Metzler CM. 1969. A mathematical model for the pharmacokinetics of LSD effect. Clin Pharmacol Ther. 10:737–740.
   PubMed Web of Science ®Google Scholar
• Nakahara Y, Kikura R, Takahashi K, Foltz RL, Mieczkowski T. 1996. Detection of LSD and metabolite in rat hair and human hair. J Anal Toxicol. 20:323–329.
   PubMed Web of Science ®Google Scholar
• Nichols DE. 2004. Hallucinogens. Pharmacol Ther. 101:131–181.
   PubMed Web of Science ®Google Scholar
• Nichols DE. 2016. Psychedelics. Pharmacol Rev. 68:264–355.
   PubMed Web of Science ®Google Scholar
• Nichols DE, Grob CS. 2018. Is LSD toxic? Forensic Sci Int. 284:141–145.
   PubMed Web of Science ®Google Scholar
• Niwaguchi T, Inoue T, Sakai T. 1974. Studies on the in vitro metabolism of compounds related to lysergic acid diethylamide (LSD). Biochem Pharmacol. 23:3063–3066.
   PubMed Web of Science ®Google Scholar
• O’Brien CP. 2001. Drug addiction and drug abuse. In: Hardman JG, Molinoff PB, Ruddon RW, Gilman AG, editor. Goodman and Gilman’s the pharmacological basis of therapeutics. New York (NY): McGraw-Hill; p. 574–639.
   Google Scholar
• Osmond H. 1957. A review of the clinical effects of psychotomimetic agents. Ann N Y Acad Sci. 66:418–434.
   PubMed Web of Science ®Google Scholar
• Parker RJ, Hirom PC, Millburn P. 1980. Enterohepatic recycling of phenolphthalein, morphine, lysergic acid diethylamide (LSD) and diphenylacetic acid in the rat. Hydrolysis of glucuronic acid conjugates in the gut lumen. Xenobiotica. 10:689–703.
   PubMed Web of Science ®Google Scholar
• Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. 2008. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 14:295–314.
   PubMed Web of Science ®Google Scholar
• Peel H, Boynton A. 1980. Analysis of LSD in urine using radioimmunoassay – excretion and storage effects. J Can Soc Forensic Sci. 13:23–28.
   Google Scholar
• Poch GK, Klette KL, Hallare DA, Manglicmot MG, Czarny RJ, McWhorter LK, Anderson CJ. 1999. Detection of metabolites of lysergic acid diethylamide (LSD) in human urine specimens: 2-oxo-3-hydroxy-LSD, a prevalent metabolite of LSD. J Chromatogr B Biomed Sci Appl. 724:23–33.
   PubMed Web of Science ®Google Scholar
• Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stampfli P, Liechti ME, Seifritz E, Vollenweider FX. 2017. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol. 27:451–457.
   PubMed Web of Science ®Google Scholar
• Reuschel SA, Eades DM, Foltz RL. 1999. Recent advances in chromatographic and mass spectrometric methods for determination of LSD and its metabolites in physiological specimens. J Chromatogr B Biomed Sci Appl. 733:145–159.
   PubMed Web of Science ®Google Scholar
• Reuschel SA, Percey SE, Liu S, Eades DM, Foltz RL. 1999. Quantitative determination of LSD and a major metabolite, 2-oxo-3-hydroxy-LSD, in human urine by solid-phase extraction and gas chromatography-tandem mass spectrometry. J Anal Toxicol. 23:306–312.
   PubMed Web of Science ®Google Scholar
• Richeval C, Allorge D, Vanhoye X, Gaulier JM. 2017. LSD detection and interpretation in hair. Curr Pharm Des. 23:5496–5501.
   PubMed Web of Science ®Google Scholar
• Rickli A, Moning OD, Hoener MC, Liechti ME. 2016. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 26:1327–1337.
   PubMed Web of Science ®Google Scholar
• Rohrich J, Zorntlein S, Becker J. 2000. Analysis of LSD in human body fluids and hair samples applying ImmunElute columns. Forensic Sci Int. 107:181–190.
   PubMed Web of Science ®Google Scholar
• Rothlin E. 1956. Metabolism of lysergic acid diethylamide. Nature. 178:1400.
   PubMed Web of Science ®Google Scholar
• Ruck CA, Bigwood J, Staples D, Ott J, Wasson RG. 1979. Entheogens. J Psychedelic Drugs. 11:145–146.
   PubMed Web of Science ®Google Scholar
• Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Muller F, Borgwardt S, Liechti ME. 2015. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 78:544–553.
   PubMed Web of Science ®Google Scholar
• Siddik ZH, Barnes RD, Dring LG, Smith RL, Williams RT. 1975. The fate of lysergic acid Di [14C] ethylamide ([14C] LSD) in the rat. Biochem Soc Trans. 3:290–292.
   PubMed Web of Science ®Google Scholar
• Siddik ZH, Barnes RD, Dring LG, Smith RL, Williams RT. 1979. The metabolism of lysergic acid DI [14C] ethylamide ([14C] LSD) in the isolated perfused rat liver. Biochem Pharmacol. 28:3081–3091.
   PubMed Web of Science ®Google Scholar
• Sklerov JH, Kalasinsky KS, Ehorn CA. 1999. Detection of lysergic acid diethylamide (LSD) in urine by gas chromatography-ion trap tandem mass spectrometry. J Anal Toxicol. 23:474–478.
   PubMed Web of Science ®Google Scholar
• Sklerov JH, Magluilo J, Jr., Shannon KK, Smith ML. 2000. Liquid chromatography-electrospray ionization mass spectrometry for the detection of lysergide and a major metabolite, 2-oxo-3-hydroxy-LSD, in urine and blood. J Anal Toxicol. 24:543–549.
   PubMed Web of Science ®Google Scholar
• Skopp G, Potsch L, Mattern R, Aderjan R. 2002. Short-term stability of lysergic acid diethylamide (LSD), N-desmethyl-LSD, and 2-oxo-3-hydroxy-LSD in urine, assessed by liquid chromatography-tandem mass spectrometry. Clin Chem. 48:1615–1618.
   PubMed Web of Science ®Google Scholar
• Slaytor MB, Wright SE. 1962. The metabolites of ergometrine and lysergic acid diethylamide in rat bile. J Med Pharm Chem. 91:483–491.
   PubMedGoogle Scholar
• Steuer AE, Poetzsch M, Stock L, Eisenbeiss L, Schmid Y, Liechti ME, Kraemer T. 2017. Development and validation of an ultra-fast and sensitive microflow liquid chromatography-tandem mass spectrometry (MFLC-MS/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans. Drug Test Anal. 9:788–797.
   PubMed Web of Science ®Google Scholar
• Stoll A, Rothlin E, Rutschmann J, Schalch WR. 1955. Distribution and fate of 14C-labeled lysergic acid diethylamide (LSD 25) in the animal body. Experientia. 11:396–397.
   PubMedGoogle Scholar
• Sullivan AT, Twitchett PJ, Fletcher SM, Moffat AC. 1978. The fate of LSD in the body: forensic considerations. J Forensic Sci Soc. 18:89–98.
   PubMedGoogle Scholar
• Szara S. 1963. Enzymatic formation of a phenolic metabolite from lysergic acid diethylamide by rat liver microsomes. Life Sci. 2:662–670.
   Google Scholar
• Taunton-Rigby A, Sher SE, Kelley PR. 1973. Lysergic acid diethylamide: radioimmunoassay. Science. 181:165–166.
   PubMed Web of Science ®Google Scholar
• Twitchett PJ, Fletcher SM, Sullivan AT, Moffat AC. 1978. Analysis of LSD in human body fluids by high-performance liquid chromatography, fluorescence spectroscopy and radioimmunoassay. J Chromatogr. 150:73–84.
   PubMed Web of Science ®Google Scholar
• Upshall D, Wailling D. 1972. The determination of LSD in human plasma following oral administration. Clin Chim Acta. 36:67–73.
   PubMed Web of Science ®Google Scholar
• Wagmann L, Richter LH, Kehl T, Wack F, Bergstrand MP, Brandt SD, Stratford A, Maurer HH, Meyer MR. 2019. In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. Anal Bioanal Chem. 19:4751–4763.
   PubMed Web of Science ®Google Scholar
• Wagner JG, Aghajanian GK, Bing OH. 1968. Correlation of performance test scores with “tissue concentration” of lysergic acid diethylamide in human subjects. Clin Pharmacol Ther. 9:635–638.
   PubMed Web of Science ®Google Scholar